1. Teva Pharmaceutical Industries reported lower-than-expected third-quarter earnings, with generic drug sales dropping from $3.01 billion in Q3 of 2016 to $3.26 billion in Q3 of 2017. Sales of branded multiple sclerosis drug Copaxone decreased 7%, to $987 million, in the wake of the arrival of generic competition. (Reuters)

2. Boehringer Ingelheim and biopharmaceutical company Dicerna Pharmaceuticals entered into a research and licensing deal in chronic liver disease drugs. BI will pay Dicerna $100 million up front and up to $191 million more in milestone payments and R&D reimbursements. (Endpoints News)

3. In two Phase-III trials, AstraZeneca’s experimental asthma drug tralokinuma failed to reduce the severity of the condition and eliminate the need for steroids. (WSJ)

4. Google announced that four health startup companies — Augmedix, BrainQ, Byteflies, and Cytovale — will join its Launchpad Studio. The unit pairs startups with Google mentors, helps emerging companies with community engagement, data management, and prototyping. (HealthcareITNews)

5. Philips said it expects to grow up to 6% as it focuses its business on health technology in the next three years. The company, which now sells medical scanners and other hospital equipment, generated 17 billion euros ($19.8 billion) in health technology sales in 2016. (Reuters)